24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Licensing
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:05
“The Israeli high-tech sector stands at a pivotal crossroads”
11:03
Full list of Israeli startup M&As in 2025
11:00
Zencity acquires UK’s Commonplace to expand global community engagement
10:28
Gong signs $8.45 million lease as it expands its R&D center in Ramat Gan
More stories
Buzz
Most popular
Daily
Weekly
1
Sam Altman-backed Apex Security in advanced talks to be acquired by Varonis for up to $40M
2
"Everyone will be a manager" - what the world of work will look like with AI agents
3
Facial recognition firm Oosto, formerly AnyVision, sold for $125M after raising $352M
4
What went wrong at AnyVision? Lessons from a $352M flameout
5
Mitiga raises $30M Series B to defend cloud services from cyberattacks
More news
Licensing
4 stories about Licensing
Israeli roads off-limits to Tesla Cybertruck due to licensing issues
18.07.24
|
Tomer Hadar
Ministry of Transportation holds back approval over bulletproof concerns
“Licensing practices are tilting the market in favor of certain providers against others”
07.05.22
|
James Spiro
Francisco Mingorance, Executive General at CISPE, explains how cloud monopolies are affecting licensing agreements online
Israel to Set Up Fast Track for Licensing Fintech Projects
19.08.19
|
Meir Orbach
According to the Israeli Ministry of Finance, there are currently 2,000 different entities awaiting licensing, many of which are fintech and blockchain companies that need to make only slight adjustments to comply with current regulations
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
Please ensure Javascript is enabled for purposes of
website accessibility